Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene/Conjugated Estrogens for Vasomotor Symptoms (SMART-2)
NCT00234819Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bazedoxifene in vasomotor symptoms (3 arms), sponsored by Pfizer. Primary endpoints: Number of moderate and severe hot flashes at 12 weeks and Severity of moderate and severe hot flashes at 12 weeks. Started Oct 2005; status: completed.
02
Drugs
bazedoxifene
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00234819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234819.